Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
WU-NK-101 by Wugen for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
WU-NK-101 is under clinical development by Wugen and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
WU-NK-101 by Wugen for Refractory Acute Myeloid Leukemia: Likelihood of Approval
WU-NK-101 is under clinical development by Wugen and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...
WU-NK-101 by Wugen for Refractory Acute Myeloid Leukemia: Likelihood of Approval
WU-NK-101 is under clinical development by Wugen and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...
WU-NK-101 by Wugen for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
WU-NK-101 is under clinical development by Wugen and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...